[go: up one dir, main page]

SG11201607183PA - Piperidine derivatives as orexin receptor antagonist - Google Patents

Piperidine derivatives as orexin receptor antagonist

Info

Publication number
SG11201607183PA
SG11201607183PA SG11201607183PA SG11201607183PA SG11201607183PA SG 11201607183P A SG11201607183P A SG 11201607183PA SG 11201607183P A SG11201607183P A SG 11201607183PA SG 11201607183P A SG11201607183P A SG 11201607183PA SG 11201607183P A SG11201607183P A SG 11201607183PA
Authority
SG
Singapore
Prior art keywords
receptor antagonist
piperidine derivatives
orexin receptor
orexin
piperidine
Prior art date
Application number
SG11201607183PA
Inventor
Haiying He
Songliang Wu
Yang Zhang
Biao Ma
Yuan Chen
Yuhe Wang
Shuhui Chen
Qiang Lv
Jiong Lan
Xing Liu
Original Assignee
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Yangtze River Pharm Group Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54054589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201607183P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Haiyan Pharmaceutical Technology Co Ltd, Yangtze River Pharm Group Co filed Critical Shanghai Haiyan Pharmaceutical Technology Co Ltd
Publication of SG11201607183PA publication Critical patent/SG11201607183PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
SG11201607183PA 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist SG11201607183PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410081220 2014-03-06
PCT/CN2015/073330 WO2015131773A1 (en) 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist

Publications (1)

Publication Number Publication Date
SG11201607183PA true SG11201607183PA (en) 2016-10-28

Family

ID=54054589

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900536TA SG10201900536TA (en) 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist
SG11201607183PA SG11201607183PA (en) 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201900536TA SG10201900536TA (en) 2014-03-06 2015-02-27 Piperidine derivatives as orexin receptor antagonist

Country Status (16)

Country Link
US (1) US10100047B2 (en)
EP (1) EP3115362B1 (en)
JP (1) JP6262885B2 (en)
KR (1) KR101920472B1 (en)
CN (1) CN106414439B (en)
AU (1) AU2015226679B2 (en)
CA (1) CA2941663C (en)
CL (1) CL2016002240A1 (en)
IL (1) IL247584A0 (en)
MX (1) MX2016011549A (en)
NZ (1) NZ723671A (en)
PE (1) PE20170184A1 (en)
RU (1) RU2669701C2 (en)
SG (2) SG10201900536TA (en)
WO (1) WO2015131773A1 (en)
ZA (1) ZA201606141B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161035A1 (en) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc COMPOUNDS AND USES OF THESE FOR THE MODULATION OF HEMOGLOBIN
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
CN106349228B (en) 2015-07-17 2019-07-09 广东东阳光药业有限公司 Substituted quinazolinone compounds and preparation method and use thereof
CN107709318B (en) 2015-08-14 2020-09-25 上海海雁医药科技有限公司 Preparation method of orexin receptor antagonist receptor compound and its intermediate and crystal form
CA3005918C (en) 2015-11-23 2023-10-17 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
US10508083B2 (en) 2016-02-04 2019-12-17 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
JP7478839B2 (en) * 2020-04-17 2024-05-07 上海海雁醫藥科技有限公司 Solid pharmaceutical formulations, and methods for their manufacture and use
CN112480107B (en) * 2020-11-30 2022-08-16 上海海雁医药科技有限公司 Substituted azabicyclooctane compounds, intermediates therefor and processes for their preparation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501859A (en) * 2003-05-13 2007-02-01 シェーリング コーポレイション Bridged n-arylsulfonylpiperidines as γ-secretase inhibitors
US20090247499A1 (en) * 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
JP2010527924A (en) * 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション Oxo-bridged diazepan orexin receptor antagonist
ES2379744T3 (en) * 2007-05-23 2012-05-03 Merck Sharp & Dohme Corp. Pyridyl-piperidine antagonists of orexin receptors
US8030495B2 (en) * 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
ES2528129T3 (en) * 2008-02-06 2015-02-04 Msd K.K. Sulfonyl piperazine derivative substituted at position 3
EP2247586B1 (en) * 2008-02-21 2012-04-25 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
US8357700B2 (en) * 2008-10-21 2013-01-22 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
WO2010048014A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
EP2350066B1 (en) * 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2739916A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2563780B1 (en) * 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
AU2011283684B2 (en) * 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
EP2730573A4 (en) * 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd METHYLPIPERIDINE DERIVATIVE
AR088352A1 (en) * 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
EP2752410B1 (en) * 2011-10-25 2016-08-31 Shionogi & Co., Ltd. Heterocycle derivative having pgd2 receptor antagonist activity
JOP20130213B1 (en) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co Oppositions to the 5-HT3 Future
CN104918939B (en) * 2012-11-16 2018-08-28 默沙东公司 Purine inhibitor of human phosphatidylinositol 3-kinase delta
TWI621618B (en) * 2013-03-13 2018-04-21 比利時商健生藥品公司 Substituted 2-azabicyclics and their use as orexin receptor modulators
TW201444849A (en) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators

Also Published As

Publication number Publication date
NZ723671A (en) 2017-05-26
CA2941663A1 (en) 2015-09-11
JP2017507185A (en) 2017-03-16
IL247584A0 (en) 2016-11-30
RU2016130937A (en) 2018-04-09
CN106414439A (en) 2017-02-15
SG10201900536TA (en) 2019-02-27
PE20170184A1 (en) 2017-04-07
ZA201606141B (en) 2017-05-31
MX2016011549A (en) 2017-05-08
AU2015226679A1 (en) 2016-09-15
US10100047B2 (en) 2018-10-16
JP6262885B2 (en) 2018-01-17
WO2015131773A1 (en) 2015-09-11
AU2015226679B2 (en) 2017-05-25
KR20160143668A (en) 2016-12-14
RU2669701C2 (en) 2018-10-15
CA2941663C (en) 2020-02-18
KR101920472B1 (en) 2019-02-08
CN106414439B (en) 2017-12-08
US20170233385A1 (en) 2017-08-17
EP3115362B1 (en) 2019-06-12
EP3115362A1 (en) 2017-01-11
CL2016002240A1 (en) 2017-02-17
EP3115362A4 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
IL256548A (en) Phenoxymethyl derivatives
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
IL250888A0 (en) Substituted piperidine compounds
EP3030233A4 (en) Oxazole orexin receptor antagonists
DK3143037T3 (en) ALPHA4BETA7-INTEGRIN-THIOETHER-PEPTIDE ANTAGONISTS
IL247728A0 (en) Pyridyl piperidines
ZA201606141B (en) Piperidine derivatives as orexin receptor antagonist
DK3212637T3 (en) DOPAMIN-D3 RECEPTOR ANTAGONIST COMPOUNDS
IL258737A (en) Ep4 antagonists
GB201420208D0 (en) Barrier
IL251027A0 (en) Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
GB201416346D0 (en) Spirocyclic derivatives
GB201421577D0 (en) Drill
GB201416352D0 (en) Spirocyclic derivatives
IL256496B (en) Novel 5-ht2 antagonists
ZA201704462B (en) New benzimidazole derivatives as antihistamine agents
GB201421576D0 (en) Drill
IL259726B (en) Piperidinyl nociceptin receptor compounds
TWM489716U (en) Drill structure
GB201405500D0 (en) Rail
EP3134092A4 (en) Pharmaceutical salts of an orexin receptor antagonist
EP3388423A4 (en) Nk1 receptor antagonist
SMT202000371T1 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
GB201411305D0 (en) Hanging tool